[et_pb_section fb_built=”1″ admin_label=”Listings” module_id=”target group” _builder_version=”4.27.5″ _module_preset=”default” background_color=”#FFFFFF” background_enable_image=”off” background_size=”custom” background_image_width=”90%” background_position=”bottom_right” top_divider_height=”51px” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row use_custom_gutter=”on” gutter_width=”3″ _builder_version=”4.27.5″ _module_preset=”default” width=”100%” custom_margin=”|auto|-1px|auto|false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_post_title meta=”off” featured_image=”off” _builder_version=”4.27.5″ _module_preset=”default” title_text_color=”#10344C” title_font_size=”45px” custom_margin=”||15px|||” global_colors_info=”{}”][\/et_pb_post_title][et_pb_text _builder_version=”4.27.5″ _module_preset=”1f09816e-184e-4ce5-a4cf-b39c52c423ca” text_font=”–et_global_body_font||||||||” text_text_color=”#10344C” text_font_size=”20px” text_line_height=”1.8em” ul_line_height=”1.8em” custom_margin=”||||false|false” hover_enabled=”0″ text_font_size_tablet=”15px” text_font_size_phone=”14px” text_font_size_last_edited=”on|phone” header_font_size_tablet=”55px” header_font_size_last_edited=”off|desktop” global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
ClinicalTrials.gov ID:<\/strong> NCT05535946 Official title:<\/strong> Study overview:<\/strong> This study is the maintenance phase of the two previous induction studies ABX464-105 and ABX464-106.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" ClinicalTrials.gov ID: NCT05535946Sponsor: Abivax S.A. Information provided by: Abivax S.A. (responsible party) Official title:A randomized, double-blind, multicenter Phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as maintenance therapy in patients with moderately to severely active ulcerative colitis. Study overview:Multicenter, randomized, placebo-controlled study to investigate […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[37,36],"tags":[],"class_list":["post-402","post","type-post","status-publish","format-standard","hentry","category-active-recruitment-completed","category-for-study-partners"],"yoast_head":"\n
Sponsor:<\/strong> Abivax S.A. Information provided by: Abivax S.A. (responsible party)<\/p>\n
A randomized, double-blind, multicenter Phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as maintenance therapy in patients with moderately to severely active ulcerative colitis.<\/p>\n
Multicenter, randomized, placebo-controlled study to investigate the long-term efficacy and safety of ABX464 (50 mg and 25 mg, once daily) as maintenance therapy in patients with moderately to severely active ulcerative colitis who have responded inadequately, not at all, or no longer to conventional therapies or have not tolerated them (e.g., corticosteroids, immunosuppressants such as azathioprine, 6-mercaptopurine, methotrexate) and\/or to advanced therapies (biologics such as TNF inhibitors, anti-integrins, anti-IL-23, S1P receptor modulators, and\/or JAK inhibitors).<\/p>\n